Page 101 - GPD-4-1

Gene & Protein in Disease Oral-ERT in PD knockout mice with tobrhGAA

Availability of data 12. Martiniuk F, Chen A, Mack A, et al. Carrier frequency for
glycogen storage disease type II in New York and estimates
Data are available from the corresponding author upon of affected individuals born with the disease. Am J Med
reasonable request. Genet. 1998;79:69-72.

References doi: 10.1002/(sici)1096-8628(19980827)79:1<69:aid-
ajmg16>3.0.co;2-k
1. Slonim A, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F.
Identification of two subtypes of infantile acid maltase 13. Park KS. Carrier frequency and predicted genetic prevalence
deficiency: Evaluation of twenty-two patients and review of of Pompe disease based on a general population database.
the literature. J Pediatr. 2000;137:283-285. Mol Genet Metab Rep. 2021;27:100734.
doi: 10.1016/j.ymgmr.2021.100734
doi: 10.1067/mpd.2000.107112
14. Colburn R, Lapidus D. An analysis of Pompe newborn
2. Engel AG. Acid maltase deficiency. In: Engel AG, Franzini-
Armstrong C, editors. Myology. New York: McGraw Hill, screening data: A new prevalence at birth, insight and
Inc.; 1994. p. 1533. discussion. Front Pediatr. 2024;11:1221140.
doi: 10.3389/fped.2023.1221140
3. Reuser AJJ, Kroos M, Willemsen R, Swallow D, Tager JM,
Galjaard H. Clinical diversity in glycogenosis type II. J Clin 15. Reuser AJ, Kroos M, Elferink RP, Tager JM. Defects in
Invest. 1987;79:1689-1699. synthesis, phosphorylation, and maturation of acid alpha
glucosidase. J Biol Chem. 1985;260:8336-8341.
doi: 10.1172/JCI113008
16. Strothotte S, Strigl-Pill N, Grunert B, et al. Enzyme
4. Beratis N, LaBadie GU, Hirschhorn R. Genetic heterogeneity
in acid alpha glucosidase deficiency. Am J Hum Genet. replacement therapy with alglucosidase alfa in 44 patients
1983;35(1):21-33. with late-onset glycogen storage disease type 2:12-
month results of an observational clinical trial. J Neurol.
5. Tagers JM, Oude Elferink RPJ, Reuser AJJ, et al. Alpha 2010;257:91-97.
glucosidase deficiency; Pompe’s disease. Enzyme.
1987;38:280-285. 17. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized
study of alglucosidase alfa in late-onset Pompe’s disease.
6. van den Hout HM, Hop W, van Diggelen OP, et al. The N Engl J Med. 2010;362:1396-1406.
natural course of infantile Pompe’s disease: 20 original cases
compared with 133 cases from the literature. Pediatrics. doi: 10.1056/NEJMoa0909859
2003;112:332-340. 18. Douillard-Guilloux G, Raben N, Takikita S, et al. Restoration
of muscle functionality by genetic suppression of glycogen
doi: 10.1542/peds.112.2.332
synthesis in a murine model of Pompe disease. Hum Mol
7. Winkel LP, Hagemans ML, van Doorn PA, et al. The natural Genet. 2010;19:684-696.
course of non-classic Pompe’s disease; a review of 225 doi: 10.1093/hmg/ddp535
published cases. J Neurol. 2005;252:875-884.
19. Lim JA, Li L, Raben N. Pompe disease: From pathophysiology
doi: 10.1007/s00415-005-0922-9
to therapy and back again. Front Aging Neurosci. 2014;6:177.
8. Engel AG, Gomez MR, Seybold ME, Lambert EH. The doi: 10.3389/fnagi.2014.00177
spectrum and diagnosis of acid maltase deficiency.
Neurology. 1973;23:95-106. 20. van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, et al.
Enzyme therapy and immune response in relation to CRIM
doi: 10.1212/wnl.23.1.95
status: The Dutch experience in classic infantile Pompe
9. Mehler M, DiMauro S. Residual acid maltase activity in late- disease. J Inherit Metab Dis. 2015;38:305-314.
onset acid maltase deficiency. Neurology. 1997;27:178-184.
doi: 10.1007/s10545-014-9707-6
doi: 10.1212/wnl.27.2.178
21. Lacana E, Yao LP, Pariser AR, Rosenberg AS. The role of
10. La Badie GU. Biochemical and Immunologic Studies of Acid immune tolerance induction in restoration of the efficacy of
Alpha Glucosidase Deficiency, a Genetically Heterogeneous, ERT in Pompe disease. Am J Med Genet Part C Semin Med
Inherited Neuromuscular Disease. Ph.D. Thesis, City Genet. 2012;160C:30-39.
University of New York, Mt. Sinai Hospital; 1986.
doi: 10.1002/ajmg.c.31316
11. Raben N, Ralston E, Chien YH, et al. Differences in the
predominance of lysosomal and autophagic pathologies 22. Bali DS, Goldstein JL, Banugaria S, et al. Predicting cross-
reactive immunological material (CRIM) status in Pompe
between infants and adults with Pompe disease: Implications disease using GAA mutations: Lessons learned from
for therapy. Mol Genet Metab. 2010;101:324-331.
10 years of clinical laboratory testing experience. Am J Med
doi: 10.1016/j.ymgme.2010.08.001 Genet Part C Semin. 2012;160C:40-49.

Volume 4 Issue 1 (2025) 15 doi: 10.36922/gpd.1760